Merus N.V.

NasdaqGM:MRUS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Netherlands

Market Cap

USD 3.95 B

Share Price

USD 52.59

Avg Daily Volume

1,165,230

Change (1 day)

-0.92%

Change (1 year)

-3.04%

Change (YTD)

25.06%

Merus N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 54.73 M

Merus N.V. Revenue is USD 54.73 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 42.77% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Merus N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 38.34 M, a -11.73% change year over year.
Merus N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 43.43 M, a -17.14% change year over year.
Merus N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 52.41 M, a 63.83% change year over year.
Merus N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 31.99 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGM: MRUS

Merus N.V.

CEO	Dr. Sven Ante Lundberg M.D.
IPO Date	May 19, 2016
Location	Netherlands
Headquarters	Yalelaan 62
Employees	260
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.